TAMPA, Fla., October 04, 2021--Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences for the Continued Research and Development of Lantibiotics.

Oragenics Inc (NYSE: OGEN) has initiated a hamster challenge study to evaluate the immunogenicity and viral load reduction impact of its COVID-19 vaccine candidate. Related Content: Oragenics's New Preclinical Data Supports Its Approach For COVID-19 Vaccine Development. The study will provide data for several vaccine formulations, using adjuvants specific for both intranasal and intramuscular routes of administration. An assessment of cross-neutralization titers against the Wuhan, Beta, and Delt

TAMPA, Fla., September 15, 2021--Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Companies in the news are: DSPG, IDEX, OGEN, AFRM

Oragenics Inc's (NYSE: OGEN) stabilized pre-fusion spike protein trimer generates neutralizing antibodies in mice after immunization against SARS-CoV-2 when administered with several intramuscular (IM) and intranasal (IN) adjuvants. The expression platform is developed by Oragenics' Canadian collaborator and licensed from the National Institutes of Health (NIH). The platform will expedite the evaluation of hybrid SARS-CoV-2 antigen candidates scheduled to be evaluated in a hamster viral challeng

TAMPA, Fla., August 30, 2021--Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants

TAMPA, Fla., August 24, 2021--Oragenics Announces Postponement of Annual Meeting of Shareholders

TAMPA, Fla., July 27, 2021--Oragenics Enters into Licensing Agreement with the National Research Council of Canada to Pursue the Rapid Development of Next-Gen SARS-CoV-2 Vaccines